Heterocyclic compounds as EphA4 inhibitors
US12290516B2 · kind B2 · utility
0Cited by
4References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2018 |
| Grant date | May 6, 2025 |
| Priority date | — |
| Expiry date | Jun 20, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/573
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New methods and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. The method includes administering to a subject in need thereof an effective amount of a small molecule compound inhibitor for EphA4 signaling. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.